and you're convinced he'll make the same mistakes all over again? I think the opposite: he learned what NOT to repeat. Also, and Randy you of all people should know this well: While Ahn is certainly one portion of the equation leading to possible success or failure, NeuVax is the other, and the most important variable. Right now NeuVax is heading down a straight path towards a highly probable FDA approval. Even if Ahn were the least capable leader (which i do NOT believe to be the case) in the emerging pharma industry - even then this company stands a very good chance of proving its case with the FDA and then being promptly bought out!!!